<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02888171</url>
  </required_header>
  <id_info>
    <org_study_id>F160318006</org_study_id>
    <nct_id>NCT02888171</nct_id>
  </id_info>
  <brief_title>Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency</brief_title>
  <official_title>Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With Moderate to Severe Chronic Kidney Disease (CKD) With Iron Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of the study is to compare the impact of oral ferric citrate compared to
      standard of care oral ferrous sulfate on serum iron, percent transferrin saturation,
      ferritin, hepcidin and hemoglobin levels in individuals with moderate to severe chronic
      kidney disease (CKD) and absolute iron deficiency.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ferric citrate is an FDA-approved oral phosphorus binder that has been shown to be effective
      in reducing serum phosphorus and fibroblast growth factor 23 (FGF23) concentrations and
      increasing iron stores and hemoglobin in individuals with non-dialysis-dependent CKD who have
      iron-deficiency anemia. This may prove to be advantageous in individuals with pre-dialysis
      CKD who require iron supplementation for iron-deficiency anemia. This is because ferric
      citrate may not only restore iron stores in individuals who are iron deficient, but by
      lowering FGF23 concentrations, ferric citrate may increase local and systemic concentrations
      of 1,25-dihydroxyvitamin D, a powerful inhibitor of hepcidin synthesis, potentially
      attenuating the increase in hepcidin following oral iron supplementation. When compared to
      standard iron supplementation therapies (e.g., oral ferrous sulfate) that powerfully
      stimulate hepcidin secretion, this may then allow for greater iron bioavailability by
      increasing iron absorption in the gut while also reducing the degree of iron sequestration in
      reticuloendothelial system stores. However, little is known about the comparative
      effectiveness of treatment with oral ferric citrate vs. oral ferrous sulfate (currently the
      standard of care) in increasing iron stores and hemoglobin in iron-deficient CKD patients. If
      ferric citrate is shown to not only improve overall iron status, but also partially mitigate
      the long-term effects of iron supplementation on hepcidin secretion by increasing
      endogenously produced 1,25-dihydroxyvitamin D, this may indicate that ferric citrate can
      provide superior short- and long-term effects on iron-restricted erythropoiesis in CKD as
      compared to the current standard of care. The main objectives of the study are to compare the
      impact of ferric citrate compared to standard of care ferrous sulfate on serum iron, percent
      transferrin saturation (TSAT), ferritin, hemoglobin and hepcidin concentrations in
      individuals with moderate to severe CKD and absolute iron deficiency.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2016</start_date>
  <completion_date type="Actual">March 30, 2019</completion_date>
  <primary_completion_date type="Actual">February 12, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Ferritin From Baseline to End of Treatment</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>The change in serum ferritin concentrations from the baseline of the study to the 12 week time point.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Transferrin Saturation From Baseline to End of Treatment</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>The change in serum transferrin saturation from the baseline to the end of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Hemoglobin From Baseline to End of Treatment</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>The change in hemoglobin concentrations from the baseline visit to the 12-week time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hepcidin From Baseline to the End of Treatment</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>The change in hepcidin concentrations from the baseline visit to the 12-week time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fibroblast Growth Factor 23 From Baseline to the End of Treatment</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>The change in fibroblast growth factor 23 concentrations from the baseline visit to the 12-week time point.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <condition>Iron Deficiency</condition>
  <condition>Anemia</condition>
  <arm_group>
    <arm_group_label>ferric citrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to the ferric citrate arm will receive 2 grams of ferric citrate three times a day with each meal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ferrous sulfate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants randomized to the ferrous sulfate arm will receive 325 mg of ferrous sulfate three times a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ferric citrate</intervention_name>
    <description>Participants randomized to the ferric citrate arm will take 2 grams of ferric citrate three times a day with meals.</description>
    <arm_group_label>ferric citrate</arm_group_label>
    <other_name>Auryxia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ferrous sulfate</intervention_name>
    <description>Participants randomized to the ferrous sulfate arm will take 325 mg of ferrous sulfate three times a day.</description>
    <arm_group_label>ferrous sulfate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years or greater

          -  Moderate to severe CKD not requiring dialysis (eGFR 15 - 45 ml/min/1.73 m2 by CKD-EPI)

          -  Absolute iron deficiency (serum ferritin &lt;300ng/ml and Transferrin Saturation &lt; 30%)

        Exclusion Criteria:

          -  Hemoglobin concentrations &gt; 13 g/dL

          -  Known disorder of iron homeostasis (e.g., hemochromatosis)

          -  Known gastrointestinal disorder (irritable bowel disease, inflammatory bowel disease)

          -  Known liver disease (ALT/AST or bilirubin &gt; 3x normal)

          -  Serum phosphorus concentrations &lt; 3.0 mg/dL

          -  Any known cause of anemia other than iron deficiency or CKD (e.g., sickle cell anemia)

          -  Symptomatic gastrointestinal bleeding within 12 weeks prior to the screening visit.

          -  Subjects receiving any form of renal replacement therapy including hemodialysis,
             peritoneal dialysis, or renal transplant.

          -  Pregnancy or lactation in female participants

          -  Severe anemia defined as a hemoglobin &lt; 8.0 g/dL for males or a hemoglobin &lt;7.0 g/dL
             for females.

          -  Receipt of erythropoiesis stimulating agents within 4 weeks of screening.

          -  Receipt of intravenous iron therapy within 8 weeks of screening.

          -  Blood transfusion within 4 weeks of screening

          -  Known allergies or severe adverse reactions to previous oral iron therapy

          -  Current use of oral phosphorus binders.

          -  Current use of an active vitamin D analog
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Orlando M Gutierrez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>August 30, 2016</study_first_submitted>
  <study_first_submitted_qc>August 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2016</study_first_posted>
  <results_first_submitted>February 11, 2020</results_first_submitted>
  <results_first_submitted_qc>March 20, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 24, 2020</results_first_posted>
  <last_update_submitted>March 20, 2020</last_update_submitted>
  <last_update_submitted_qc>March 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Orlando M. Gutierrez, MD, MMSc</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 14, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/71/NCT02888171/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited from the nephrology outpatient clinics at the University of Alabama at Birmingham (UAB) from September 2016 to October 2018.</recruitment_details>
      <pre_assignment_details>Participants who were taking oral iron supplements at the time of the screening visit were allowed to participate but had to undergo a wash-out period of at least 4 weeks prior to randomization.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ferric Citrate</title>
          <description>Participants randomized to the ferric citrate arm will receive 2 grams of ferric citrate three times a day with each meal.
ferric citrate: Participants randomized to the ferric citrate arm will take 2 grams of ferric citrate three times a day with meals.</description>
        </group>
        <group group_id="P2">
          <title>Ferrous Sulfate</title>
          <description>Participants randomized to the ferrous sulfate arm will receive 325 mg of ferrous sulfate three times a day
ferrous sulfate: Participants randomized to the ferrous sulfate arm will take 325 mg of ferrous sulfate three times a day.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ferric Citrate</title>
          <description>Participants randomized to the ferric citrate arm will receive 2 grams of ferric citrate three times a day with each meal.
ferric citrate: Participants randomized to the ferric citrate arm will take 2 grams of ferric citrate three times a day with meals.</description>
        </group>
        <group group_id="B2">
          <title>Ferrous Sulfate</title>
          <description>Participants randomized to the ferrous sulfate arm will receive 325 mg of ferrous sulfate three times a day
ferrous sulfate: Participants randomized to the ferrous sulfate arm will take 325 mg of ferrous sulfate three times a day.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" spread="12"/>
                    <measurement group_id="B2" value="63" spread="11"/>
                    <measurement group_id="B3" value="62" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>body mass index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37" spread="8"/>
                    <measurement group_id="B2" value="36" spread="9"/>
                    <measurement group_id="B3" value="36" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>systolic blood pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="136" spread="21"/>
                    <measurement group_id="B2" value="134" spread="20"/>
                    <measurement group_id="B3" value="135" spread="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>diastolic blood pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74" spread="11"/>
                    <measurement group_id="B2" value="73" spread="10"/>
                    <measurement group_id="B3" value="73" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>phosphorus</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.7" spread="0.5"/>
                    <measurement group_id="B2" value="3.9" spread="0.8"/>
                    <measurement group_id="B3" value="3.8" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>calcium</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.3" spread="0.4"/>
                    <measurement group_id="B2" value="9.3" spread="0.7"/>
                    <measurement group_id="B3" value="9.3" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>estimated glomerular filtration rate</title>
          <units>ml/min/1.73m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33" spread="12"/>
                    <measurement group_id="B2" value="26" spread="14"/>
                    <measurement group_id="B3" value="31" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>transferrin saturation</title>
          <units>%</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18" spread="6"/>
                    <measurement group_id="B2" value="19" spread="6"/>
                    <measurement group_id="B3" value="18" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ferritin</title>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90" spread="70"/>
                    <measurement group_id="B2" value="100" spread="59"/>
                    <measurement group_id="B3" value="95" spread="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>hemoglobin</title>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.4" spread="1"/>
                    <measurement group_id="B2" value="11.0" spread="1"/>
                    <measurement group_id="B3" value="11.2" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Ferritin From Baseline to End of Treatment</title>
        <description>The change in serum ferritin concentrations from the baseline of the study to the 12 week time point.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ferric Citrate</title>
            <description>Participants randomized to the ferric citrate arm will receive 2 grams of ferric citrate three times a day with each meal.
ferric citrate: Participants randomized to the ferric citrate arm will take 2 grams of ferric citrate three times a day with meals.</description>
          </group>
          <group group_id="O2">
            <title>Ferrous Sulfate</title>
            <description>Participants randomized to the ferrous sulfate arm will receive 325 mg of ferrous sulfate three times a day
ferrous sulfate: Participants randomized to the ferrous sulfate arm will take 325 mg of ferrous sulfate three times a day.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Ferritin From Baseline to End of Treatment</title>
          <description>The change in serum ferritin concentrations from the baseline of the study to the 12 week time point.</description>
          <units>percentage of change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60" spread="17"/>
                    <measurement group_id="O2" value="30" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Transferrin Saturation From Baseline to End of Treatment</title>
        <description>The change in serum transferrin saturation from the baseline to the end of treatment</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ferric Citrate</title>
            <description>Participants randomized to the ferric citrate arm will receive 2 grams of ferric citrate three times a day with each meal.
ferric citrate: Participants randomized to the ferric citrate arm will take 2 grams of ferric citrate three times a day with meals.</description>
          </group>
          <group group_id="O2">
            <title>Ferrous Sulfate</title>
            <description>Participants randomized to the ferrous sulfate arm will receive 325 mg of ferrous sulfate three times a day
ferrous sulfate: Participants randomized to the ferrous sulfate arm will take 325 mg of ferrous sulfate three times a day.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Transferrin Saturation From Baseline to End of Treatment</title>
          <description>The change in serum transferrin saturation from the baseline to the end of treatment</description>
          <units>percentage of change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40" spread="17"/>
                    <measurement group_id="O2" value="2" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Hemoglobin From Baseline to End of Treatment</title>
        <description>The change in hemoglobin concentrations from the baseline visit to the 12-week time point.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ferric Citrate</title>
            <description>Participants randomized to the ferric citrate arm will receive 2 grams of ferric citrate three times a day with each meal.
ferric citrate: Participants randomized to the ferric citrate arm will take 2 grams of ferric citrate three times a day with meals.</description>
          </group>
          <group group_id="O2">
            <title>Ferrous Sulfate</title>
            <description>Participants randomized to the ferrous sulfate arm will receive 325 mg of ferrous sulfate three times a day
ferrous sulfate: Participants randomized to the ferrous sulfate arm will take 325 mg of ferrous sulfate three times a day.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hemoglobin From Baseline to End of Treatment</title>
          <description>The change in hemoglobin concentrations from the baseline visit to the 12-week time point.</description>
          <units>percentage of change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" spread="0.1"/>
                    <measurement group_id="O2" value="0" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Hepcidin From Baseline to the End of Treatment</title>
        <description>The change in hepcidin concentrations from the baseline visit to the 12-week time point.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ferric Citrate</title>
            <description>Participants randomized to the ferric citrate arm will receive 2 grams of ferric citrate three times a day with each meal.
ferric citrate: Participants randomized to the ferric citrate arm will take 2 grams of ferric citrate three times a day with meals.</description>
          </group>
          <group group_id="O2">
            <title>Ferrous Sulfate</title>
            <description>Participants randomized to the ferrous sulfate arm will receive 325 mg of ferrous sulfate three times a day
ferrous sulfate: Participants randomized to the ferrous sulfate arm will take 325 mg of ferrous sulfate three times a day.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hepcidin From Baseline to the End of Treatment</title>
          <description>The change in hepcidin concentrations from the baseline visit to the 12-week time point.</description>
          <units>percentage of change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" spread="20"/>
                    <measurement group_id="O2" value="28" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fibroblast Growth Factor 23 From Baseline to the End of Treatment</title>
        <description>The change in fibroblast growth factor 23 concentrations from the baseline visit to the 12-week time point.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ferric Citrate</title>
            <description>Participants randomized to the ferric citrate arm will receive 2 grams of ferric citrate three times a day with each meal.
ferric citrate: Participants randomized to the ferric citrate arm will take 2 grams of ferric citrate three times a day with meals.</description>
          </group>
          <group group_id="O2">
            <title>Ferrous Sulfate</title>
            <description>Participants randomized to the ferrous sulfate arm will receive 325 mg of ferrous sulfate three times a day
ferrous sulfate: Participants randomized to the ferrous sulfate arm will take 325 mg of ferrous sulfate three times a day.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fibroblast Growth Factor 23 From Baseline to the End of Treatment</title>
          <description>The change in fibroblast growth factor 23 concentrations from the baseline visit to the 12-week time point.</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37" lower_limit="-74" upper_limit="1"/>
                    <measurement group_id="O2" value="-8" lower_limit="-32" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ferric Citrate</title>
          <description>Participants randomized to the ferric citrate arm will receive 2 grams of ferric citrate three times a day with each meal.
ferric citrate: Participants randomized to the ferric citrate arm will take 2 grams of ferric citrate three times a day with meals.</description>
        </group>
        <group group_id="E2">
          <title>Ferrous Sulfate</title>
          <description>Participants randomized to the ferrous sulfate arm will receive 325 mg of ferrous sulfate three times a day
ferrous sulfate: Participants randomized to the ferrous sulfate arm will take 325 mg of ferrous sulfate three times a day.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>change in smell</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Vision changes</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Change in stool color</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="30"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="30"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="30"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="30"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>GERD</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Weight Loss</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="30"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary frequency</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Orlando M. Gutierrez, MD</name_or_title>
      <organization>University of Alabama at Birmingham</organization>
      <phone>205-996-2736</phone>
      <email>ogutierrez@uabmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

